Drugs / PRJ1-3024
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05159700 | Mar 2022 → Jul 2024 overdue | neoplasm | Zhuhai Yufan Biotechnologies Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06727630 | Mar 2024 → Apr 2025 overdue | melanoma | Zhuhai Yufan Biotechnologies Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05315167 | May 2022 → May 2027 expected | high grade malignant neoplasm | Zhuhai Yufan Biotechnologies Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRJ1-3024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05159700 ↗ |
| Action | Inhibit | “PRJ1-3024 is a small molecular Hematopoietic progenitor kinase (HPK-1) inhibitor.” NCT06727630 ↗ |
| Modality | Small molecule | “PRJ1-3024 is a small molecular Hematopoietic progenitor kinase (HPK-1) inhibitor.” NCT06727630 ↗ |
| Route | Oral | “administered orally once a day” NCT05159700 ↗ |